{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T05:00:39Z","timestamp":1775019639874,"version":"3.50.1"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003062","name":"Erciyes University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003062","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflamm. Res."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Isocitrate dehydrogenase 1 (IDH1) mutations confer distinct biological properties to gliomas, including the reshaping of the tumor immune microenvironment. While T cell dysfunction in glioblastoma has been extensively characterized, the role of innate lymphoid cells (ILCs)-critical regulators of tissue homeostasis and early immune responses- remains poorly understood.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We investigated how IDH1 mutations and their oncometabolite D-2-hydroxyglutarate (D-2HG) influence ILC subset distribution, immune checkpoint expression, and cytokine production in glioma patients, glioma-conditioned medium (GCM) models, and in vivo mouse experiments. Tumor and peripheral blood samples from 32 glioma patients (WHO 2021 classification, grades II\u2013IV) were analyzed by flow cytometry to assess ILC subsets and immunecheckpoint molecules (PD-1, CTLA-4, KLRG1). Tonsil-derived human ILCs were co-cultured with IDH1-mutant or wild-type glioma cells and their GCM. In vitro, ILCs were exposed to graded concentrations of D-2HG, whereas in vivo studies involved intraperitoneal administration of D-2HG or L-2HG in mice to evaluate ILC distribution across lymphoid and mucosal tissues.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>IDH1-mutant gliomas exhibited increased ILC3 and decreased ILC1 frequencies in both tumor tissue and peripheral blood. ILC3s in IDH1-mutant tumors expressed higher PD-1, whereas ILC2s showed reduced PD-1 levels. In co-culture assays, IDH1-mutant glioma cells and their GCM suppressed PD-1 and CTLA-4 expression on ILCs while promoting proliferation. Exposure to D-2HG recapitulated these effects in a dose-dependent manner, reducing checkpoint expression and enhancing IFN-\u03b3 and TNF-\u03b1 secretion. In vivo, D-2HG and L-2HG differentially altered ILC subset distribution across mucosal and lymphoid compartments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>IDH1 mutations and their associated oncometabolite D-2HG remodel the innate lymphoid cell landscape in gliomas, driving an ILC3-biased phenotype with reduced checkpoint receptor expression. These findings identify ILCs as key modulators of glioma immunity and suggest that targeting innate immune pathways could complement existing immunotherapeutic approaches.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00011-026-02223-8","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T03:04:16Z","timestamp":1775012656000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["IDH1 Mutant Glioma Favors Group 3 Innate Lymphoid Cells and Is Resistant to Immune Checkpoint Expression"],"prefix":"10.1007","volume":"75","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2255-1685","authenticated-orcid":false,"given":"Serife","family":"Erdem","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yesim","family":"Haliloglu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inayet Nur","family":"Uslu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Houran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Halil","family":"Ulutabanca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alperen","family":"Vural","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehmet Berat","family":"Erturhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Halit","family":"Canatan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5816-0686","authenticated-orcid":false,"given":"Ahmet","family":"Eken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,1]]},"reference":[{"key":"2223_CR1","doi-asserted-by":"publisher","first-page":"v1","DOI":"10.1093\/neuonc\/noac202","volume":"24","author":"QT Ostrom","year":"2022","unstructured":"Ostrom QT, Price M, Neff C, Cioffi G, Waite KA, Kruchko C, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2015\u20132019. Neuro Oncol. 2022;24:v1-95. https:\/\/doi.org\/10.1093\/neuonc\/noac202.","journal-title":"Neuro Oncol"},{"key":"2223_CR2","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis DN, Perry A, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021;23:1231\u201351. https:\/\/doi.org\/10.1093\/neuonc\/noab106.","journal-title":"Neuro Oncol"},{"key":"2223_CR3","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.trecan.2015.10.009","volume":"1","author":"D Hambardzumyan","year":"2015","unstructured":"Hambardzumyan D, G B. Glioblastoma: defining tumor niches. Trends in Cancer. 2015;1:252\u201365. https:\/\/doi.org\/10.1016\/j.trecan.2015.10.009.","journal-title":"Trends in Cancer"},{"key":"2223_CR4","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1038\/NG.1004","volume":"43","author":"TC Pansuriya","year":"2011","unstructured":"Pansuriya TC, van Eijk R, d\u2019Adamo P, et al. Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in ollier disease and maffucci syndrome. Nat Genet. 2011;43:1256\u201361. https:\/\/doi.org\/10.1038\/NG.1004.","journal-title":"Nat Genet"},{"key":"2223_CR5","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1634\/THEONCOLOGIST.2011-0386","volume":"17","author":"DR Borger","year":"2012","unstructured":"Borger DR, Tanabe KK, Fan KC, et al. Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist. 2012;17:72\u20139. https:\/\/doi.org\/10.1634\/THEONCOLOGIST.2011-0386.","journal-title":"Oncologist"},{"key":"2223_CR6","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/J.CCR.2010.11.015","volume":"18","author":"ME Figueroa","year":"2010","unstructured":"Figueroa ME, Abdel-Wahab O, Lu C, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 2010;18:553\u201367. https:\/\/doi.org\/10.1016\/J.CCR.2010.11.015.","journal-title":"Cancer Cell"},{"key":"2223_CR7","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3002693.Detection","author":"OC Andronesi","year":"2013","unstructured":"Andronesi OC, Kim G, Gerstner E, Batchelor T, Tzika AA, Fantin VR, et al. Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by spectral-editing and 2D correlation magnetic resonance spectroscopy. Sci transl med. 2013. https:\/\/doi.org\/10.1126\/scitranslmed.3002693.Detection.","journal-title":"Sci transl med"},{"key":"2223_CR8","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/J.TCB.2017.06.002","volume":"27","author":"ML Gagn\u00e9","year":"2017","unstructured":"Gagn\u00e9 ML, Boulay K, Topisirovic I, et al. Oncogenic activities of IDH1\/2 mutations: from epigenetics to cellular signaling. Trends Cell Biol. 2017;27:738\u201352. https:\/\/doi.org\/10.1016\/J.TCB.2017.06.002.","journal-title":"Trends Cell Biol"},{"key":"2223_CR9","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1093\/NEUONC\/NOV136","volume":"18","author":"MS Waitkus","year":"2016","unstructured":"Waitkus MS, Diplas BH, H Y. Isocitrate dehydrogenase mutations in gliomas. Neuro Oncol. 2016;18:16\u201326. https:\/\/doi.org\/10.1093\/NEUONC\/NOV136.","journal-title":"Neuro Oncol"},{"key":"2223_CR10","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1634\/THEONCOLOGIST.2009-0218","volume":"15","author":"M Labussiere","year":"2010","unstructured":"Labussiere M, Sanson M, Idbaih A, Delattre J-Y. IDH1 gene mutations: a new paradigm in glioma prognosis and therapy? Oncologist. 2010;15:196. https:\/\/doi.org\/10.1634\/THEONCOLOGIST.2009-0218.","journal-title":"Oncologist"},{"key":"2223_CR11","doi-asserted-by":"publisher","first-page":"4026","DOI":"10.1158\/1078-0432.CCR-18-3458","volume":"25","author":"J Koh","year":"2019","unstructured":"Koh J, Kim HY, Lee Y, et al. IL23-producing human lung cancer cells promote tumor growth via conversion of innate lymphoid cell 1 (ILC1) into ILC3. Clin Cancer Res. 2019;25:4026\u201337. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-3458.","journal-title":"Clin Cancer Res"},{"issue":"OCT","key":"2223_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2016.00426","volume":"7","author":"Y Jiao","year":"2016","unstructured":"Jiao Y, Huntington ND, Belz GT, et al. Type 1 innate lymphoid cell biology: lessons learnt from natural killer cells. Front Immunol. 2016;7(OCT):1\u20138. https:\/\/doi.org\/10.3389\/fimmu.2016.00426.","journal-title":"Front Immunol"},{"key":"2223_CR13","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.cell.2016.01.002","volume":"164","author":"S Dadi","year":"2016","unstructured":"Dadi S, Chhangawala S, Whitlock BM, Franklin RA, Luo CT, Oh SA, et al. Cancer immunosurveillance by tissue-resident innate lymphoid cells and innate-like T cells. Cell. 2016;164:365\u201377. https:\/\/doi.org\/10.1016\/j.cell.2016.01.002.","journal-title":"Cell"},{"key":"2223_CR14","doi-asserted-by":"publisher","DOI":"10.1126\/SCIIMMUNOL.ABI8642","author":"BG Nixon","year":"2022","unstructured":"Nixon BG, Chou C, Krishna C, Dadi S, Michel AO, Cornish AE, et al. Cytotoxic granzyme C-expressing ILC1s contribute to antitumor immunity and neonatal autoimmunity. Sci Immunol. 2022. https:\/\/doi.org\/10.1126\/SCIIMMUNOL.ABI8642.","journal-title":"Sci Immunol"},{"key":"2223_CR15","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/J.CELL.2023.11.032","volume":"187","author":"D Kirschenbaum","year":"2024","unstructured":"Kirschenbaum D, Xie K, Ingelfinger F, Katzenelenbogen Y, Abadie K, Look T, et al. Time-resolved single-cell transcriptomics defines immune trajectories in glioblastoma. Cell. 2024;187:149-165.e23. https:\/\/doi.org\/10.1016\/J.CELL.2023.11.032.","journal-title":"Cell"},{"key":"2223_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/FIMMU.2019.00217","author":"A Eken","year":"2019","unstructured":"Eken A, Yetkin MF, Vural A, Okus FZ, Erdem S, Azizoglu ZB, et al. Fingolimod alters tissue distribution and cytokine production of human and murine innate lymphoid cells. Front Immunol. 2019. https:\/\/doi.org\/10.3389\/FIMMU.2019.00217.","journal-title":"Front Immunol"},{"key":"2223_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2023.109691","volume":"253","author":"S Erdem","year":"2023","unstructured":"Erdem S, Haskologlu S, Haliloglu Y, Celikzencir H, Arik E, Keskin O, et al. Defective treg generation and increased type 3 immune response in leukocyte adhesion deficiency 1. Clin Immunol. 2023;253:109691. https:\/\/doi.org\/10.1016\/j.clim.2023.109691.","journal-title":"Clin Immunol"},{"key":"2223_CR18","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s12026-025-09618-5","volume":"73","author":"S Erdem","year":"2025","unstructured":"Erdem S, Yilmaz E, Ozcan A, Canatan AN, Bisgin A, Dogan ME, et al. A novel loss of function mutation in the HAVCR2 gene in a patient diagnosed with hodgkin\u2019s lymphoma. Immunol Res. 2025;73:2\u20135. https:\/\/doi.org\/10.1007\/s12026-025-09618-5.","journal-title":"Immunol Res"},{"key":"2223_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10875-023-01602-8","volume":"44","author":"AL Lanz","year":"2024","unstructured":"Lanz AL, Erdem S, Ozcan A, Ceylaner G, Cansever M, Ceylaner S, et al. A novel biallelic LCK variant resulting in profound T-cell immune deficiency and review of the literature. J Clin Immunol. 2024;44:1\u201315. https:\/\/doi.org\/10.1007\/s10875-023-01602-8.","journal-title":"J Clin Immunol"},{"key":"2223_CR20","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1002\/eji.202049033","volume":"51","author":"X Yuan","year":"2021","unstructured":"Yuan X, Rasul F, Nashan BSC. Innate lymphoid cells and cancer: role in tumor progression and inhibition. Eur J Immunol. 2021;51:2188\u2013205. https:\/\/doi.org\/10.1002\/eji.202049033.","journal-title":"Eur J Immunol"},{"key":"2223_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.599253","volume":"12","author":"D Upreti","year":"2020","unstructured":"Upreti D, Bakhshinyan D, Bloemberg D, et al. Strategies to enhance the efficacy of T-cell therapy for central nervous system tumors. Front Immunol. 2020;12:599253. https:\/\/doi.org\/10.3389\/fimmu.2020.599253.","journal-title":"Front Immunol"},{"key":"2223_CR22","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1007\/s00335-018-9781-4","volume":"29","author":"C Guillerey","year":"2018","unstructured":"Guillerey C. Roles of cytotoxic and helper innate lymphoid cells in cancer. Mamm Genome. 2018;29:777\u201389. https:\/\/doi.org\/10.1007\/s00335-018-9781-4.","journal-title":"Mamm Genome"},{"key":"2223_CR23","doi-asserted-by":"publisher","first-page":"e461","DOI":"10.3324\/HAEMATOL.2016.144725","volume":"101","author":"I de Weerdt","year":"2016","unstructured":"de Weerdt I, van Hoeven V, Munneke JM, et al. Innate lymphoid cells are expanded and functionally altered in chronic lymphocytic leukemia. Haematologica. 2016;101:e461\u20134. https:\/\/doi.org\/10.3324\/HAEMATOL.2016.144725.","journal-title":"Haematologica"},{"key":"2223_CR24","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1016\/0021-8502(94)90001-9","volume":"96","author":"S Trabanelli","year":"2011","unstructured":"Trabanelli S, Curti A, Lecciso M, et al. CD127+ innate lymphoid cells are dysregulated in treatment na\u00efve acute myeloid leukemia patients at diagnosis. Hematology. 2011;96:1390\u20131. https:\/\/doi.org\/10.1016\/0021-8502(94)90001-9.","journal-title":"Hematology"},{"key":"2223_CR25","doi-asserted-by":"publisher","DOI":"10.1182\/BLOODADVANCES.2018030478","volume":"3","author":"B Salom\u00e9","year":"2019","unstructured":"Salom\u00e9 B, Gomez-Cadena A, Loyon R, et al. CD56 as a marker of an ILC1-like population with NK cell properties that is functionally impaired in AML. Blood Adv. 2019;3:3674. https:\/\/doi.org\/10.1182\/BLOODADVANCES.2018030478.","journal-title":"Blood Adv"},{"key":"2223_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/FIMMU.2019.02337","volume":"10","author":"S Romero-Su\u00e1rez","year":"2019","unstructured":"Romero-Su\u00e1rez S, Del Rio Serrato A, Bueno RJ, et al. The central nervous system contains ILC1s that differ from NK cells in the response to inflammation. Front Immunol. 2019;10:2337. https:\/\/doi.org\/10.3389\/FIMMU.2019.02337.","journal-title":"Front Immunol"},{"issue":"7","key":"2223_CR27","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/s41422-020-0312-y","volume":"30","author":"S Wang","year":"2020","unstructured":"Wang S, Qu Y, Xia P, et al. Transdifferentiation of tumor infiltrating innate lymphoid cells during progression of colorectal cancer. Cell Res. 2020;30(7):610\u201322. https:\/\/doi.org\/10.1038\/s41422-020-0312-y.","journal-title":"Cell Res"},{"key":"2223_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/CMI.2014.91","volume":"12","author":"C Sun","year":"2015","unstructured":"Sun C, Sun H, Zhang C, Tian Z. NK cell receptor imbalance and NK cell dysfunction in HBV infection and hepatocellular carcinoma. Cell Mol Immunol. 2015;12:292. https:\/\/doi.org\/10.1038\/CMI.2014.91.","journal-title":"Cell Mol Immunol"},{"key":"2223_CR29","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1038\/S41423-020-00565-9","volume":"18","author":"ST Paijens","year":"2021","unstructured":"Paijens ST, Vledder A, de Bruyn M, Nijman HW. Tumor-infiltrating lymphocytes in the immunotherapy era. Cell Mol Immunol. 2021;18:842\u201359. https:\/\/doi.org\/10.1038\/S41423-020-00565-9.","journal-title":"Cell Mol Immunol"},{"key":"2223_CR30","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/S13577-019-00257-1\/FIGURES\/1","volume":"32","author":"T Dzopali\u0107","year":"2019","unstructured":"Dzopali\u0107 T, Bo\u017ei\u0107-Nedeljkovi\u0107 B, Juri\u0161i\u0107 V. Function of innate lymphoid cells in the immune-related disorders. Hum Cell. 2019;32:231\u20139. https:\/\/doi.org\/10.1007\/S13577-019-00257-1\/FIGURES\/1.","journal-title":"Hum Cell"},{"key":"2223_CR31","doi-asserted-by":"publisher","first-page":"45","DOI":"10.4049\/JIMMUNOL.1501102","volume":"196","author":"M Salimi","year":"2016","unstructured":"Salimi M, Xue L, Jolin H, Hardman C, Cousins DJ, McKenzie ANJ, et al. Group 2 innate lymphoid cells express functional NKp30 receptor inducing type 2 cytokine production. J Immunol. 2016;196:45\u201354. https:\/\/doi.org\/10.4049\/JIMMUNOL.1501102.","journal-title":"J Immunol"},{"key":"2223_CR32","doi-asserted-by":"publisher","first-page":"2916","DOI":"10.1172\/JCI89717","volume":"127","author":"MF Chevalier","year":"2017","unstructured":"Chevalier MF, Trabanelli S, Racle J, et al. ILC2-modulated T cell-to-MDSC balance is associated with bladder cancer recurrence. J Clin Invest. 2017;127:2916\u201329. https:\/\/doi.org\/10.1172\/JCI89717.","journal-title":"J Clin Invest"},{"key":"2223_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/S41467-017-00678-2","author":"S Trabanelli","year":"2017","unstructured":"Trabanelli S, Chevalier MF, Martinez-Usatorre A, et al. Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis. Nat Commun. 2017. https:\/\/doi.org\/10.1038\/S41467-017-00678-2.","journal-title":"Nat Commun"},{"key":"2223_CR34","doi-asserted-by":"publisher","DOI":"10.1002\/FSN3.961","volume":"7","author":"W Cui","year":"2019","unstructured":"Cui W, Zhang W, Yuan X, Liu S, Li M, Niu J, et al. Vitamin A deficiency execrates Lewis lung carcinoma via induction of type 2 innate lymphoid cells and alternatively activates macrophages. Food Sci Nutr. 2019;7:1288. https:\/\/doi.org\/10.1002\/FSN3.961.","journal-title":"Food Sci Nutr"},{"key":"2223_CR35","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/J.IMMUNI.2015.05.019","volume":"43","author":"AB Molofsky","year":"2015","unstructured":"Molofsky AB, Van Gool F, Liang HE, Van Dyken SJ, Nussbaum JC, Lee J, et al. Interleukin-33 and Interferon-\u03b3 counter-regulate group 2 innate lymphoid cell activation during immune perturbation. Immunity. 2015;43:161\u201374. https:\/\/doi.org\/10.1016\/J.IMMUNI.2015.05.019.","journal-title":"Immunity"},{"key":"2223_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-018-4262-4","volume":"18","author":"M Salimi","year":"2018","unstructured":"Salimi M, Wang R, Yao X, Li X, et al. Activated innate lymphoid cell populations accumulate in human tumour tissues. BMC Cancer. 2018;18:1\u201310. https:\/\/doi.org\/10.1186\/s12885-018-4262-4.","journal-title":"BMC Cancer"},{"key":"2223_CR37","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1093\/ECCO-JCC\/JJY119","volume":"13","author":"M Forkel","year":"2019","unstructured":"Forkel M, Van Tol S, H\u00f6\u00f6g C, Micha\u00eblsson J, Almer S, Mj\u00f6sberg J. Distinct alterations in the composition of mucosal innate lymphoid cells in newly diagnosed and established crohn\u2019s disease and ulcerative colitis. J Crohns Colitis. 2019;13:67\u201378. https:\/\/doi.org\/10.1093\/ECCO-JCC\/JJY119.","journal-title":"J Crohns Colitis"},{"key":"2223_CR38","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1002\/IJC.28481","volume":"134","author":"IP Jovanovic","year":"2014","unstructured":"Jovanovic IP, Pejnovic NN, Radosavljevic GD, Pantic JM, Milovanovic MZ, Arsenijevic NN, et al. Interleukin-33\/ST2 axis promotes breast cancer growth and metastases by facilitating intratumoral accumulation of immunosuppressive and innate lymphoid cells. Int J Cancer. 2014;134:1669\u201382. https:\/\/doi.org\/10.1002\/IJC.28481.","journal-title":"Int J Cancer"},{"key":"2223_CR39","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/923135","author":"Q Bie","year":"2014","unstructured":"Bie Q, Zhang P, Su Z, Zheng D, Ying X, Wu Y, et al. Polarization of ILC2s in peripheral blood might contribute to immunosuppressive microenvironment in patients with gastric cancer. J Immunol Res. 2014. https:\/\/doi.org\/10.1155\/2014\/923135.","journal-title":"J Immunol Res"},{"key":"2223_CR40","doi-asserted-by":"publisher","first-page":"3456","DOI":"10.4049\/JIMMUNOL.1800173","volume":"201","author":"A Long","year":"2018","unstructured":"Long A, Dominguez D, Qin L, Chen S, Fan J, Zhang M, et al. Type 2 innate lymphoid cells impede IL-33-mediated tumor suppression. J Immunol. 2018;201:3456\u201364. https:\/\/doi.org\/10.4049\/JIMMUNOL.1800173.","journal-title":"J Immunol"},{"key":"2223_CR41","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1038\/S41590-020-0745-Y","volume":"21","author":"MJ Schuijs","year":"2020","unstructured":"Schuijs MJ, Png S, Richard AC, Tsyben A, Hamm G, Stockis J, et al. ILC2-driven innate immune checkpoint mechanism antagonizes NK cell antimetastatic function in the lung. Nat Immunol. 2020;21:998\u20131009. https:\/\/doi.org\/10.1038\/S41590-020-0745-Y.","journal-title":"Nat Immunol"},{"key":"2223_CR42","doi-asserted-by":"publisher","first-page":"3241","DOI":"10.1172\/JCI73742","volume":"124","author":"J Li","year":"2014","unstructured":"Li J, Razumilava N, Gores GJ, Walters S, Mizuochi T, Mourya R, et al. Biliary repair and carcinogenesis are mediated by IL-33-dependent cholangiocyte proliferation. J Clin Invest. 2014;124:3241\u201351. https:\/\/doi.org\/10.1172\/JCI73742.","journal-title":"J Clin Invest"},{"key":"2223_CR43","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/s41586-020-2015-4","volume":"579","author":"JA Moral","year":"2020","unstructured":"Moral JA, Leung J, Rojas LA, Ruan J, Zhao J, Sethna Z, et al. ILC2s amplify PD-1 blockade by activating tissue-specific cancer immunity. Nature. 2020;579:130\u20135. https:\/\/doi.org\/10.1038\/s41586-020-2015-4.","journal-title":"Nature"},{"key":"2223_CR44","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1038\/s41590-021-00943-z","volume":"22","author":"N Jacquelot","year":"2021","unstructured":"Jacquelot N, Seillet C, Wang M, et al. Blockade of the co-inhibitory molecule PD-1 unleashes ILC2-dependent antitumor immunity in melanoma. Nat Immunol. 2021;22:851\u201364. https:\/\/doi.org\/10.1038\/s41590-021-00943-z.","journal-title":"Nat Immunol"},{"key":"2223_CR45","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.4049\/JIMMUNOL.1501730","volume":"196","author":"J Kim","year":"2016","unstructured":"Kim J, Kim W, Moon UJ, Kim HJ, Choi H-J, Sin J-I, et al. Intratumorally establishing type 2 innate lymphoid cells blocks tumor growth. J Immunol. 2016;196:2410\u201323. https:\/\/doi.org\/10.4049\/JIMMUNOL.1501730.","journal-title":"J Immunol"},{"key":"2223_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2021.100353","author":"J Qi","year":"2021","unstructured":"Qi J, Crinier A, Escali\u00e8re B, Ye Y, Wang Z, Zhang T, et al. Single-cell transcriptomic landscape reveals tumor specific innate lymphoid cells associated with colorectal cancer progression. Cell Rep Med. 2021. https:\/\/doi.org\/10.1016\/j.xcrm.2021.100353.","journal-title":"Cell Rep Med"},{"key":"2223_CR47","doi-asserted-by":"publisher","first-page":"6740","DOI":"10.18632\/AGING.202531","volume":"13","author":"L Peng","year":"2021","unstructured":"Peng L, Sun W, Wei F, Chen L, Wen W. Interleukin-33 modulates immune responses in cutaneous melanoma in a context-specific way. Aging (Albany NY). 2021;13:6740\u201351. https:\/\/doi.org\/10.18632\/AGING.202531.","journal-title":"Aging (Albany NY)"},{"key":"2223_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/CANCERS13030559","volume":"13","author":"Q Huang","year":"2021","unstructured":"Huang Q, Jacquelot N, Preaudet A, Hediyeh\u2010zadeh S, Souza\u2010fonseca\u2010guimaraes F, McKenzie ANJ, et al. Type 2 innate lymphoid cells protect against colorectal cancer progression and predict improved patient survival. Cancers (Basel). 2021;13:1\u201316. https:\/\/doi.org\/10.3390\/CANCERS13030559.","journal-title":"Cancers (Basel)"},{"key":"2223_CR49","doi-asserted-by":"publisher","first-page":"2743","DOI":"10.1016\/J.CELREP.2020.01.103","volume":"30","author":"M Wagner","year":"2020","unstructured":"Wagner M, Ealey KN, Tetsu H, Kiniwa T, Motomura Y, Moro K, et al. Tumor-derived lactic acid contributes to the paucity of intratumoral ILC2s. Cell Rep. 2020;30:2743-2757.e5. https:\/\/doi.org\/10.1016\/J.CELREP.2020.01.103.","journal-title":"Cell Rep"},{"key":"2223_CR50","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1084\/jem.20122308","volume":"210","author":"S Kirchberger","year":"2013","unstructured":"Kirchberger S, Royston DJ, et al. Innate lymphoid cells sustain colon cancer through production of interleukin-22 in a mouse model. J Exp Med. 2013;210:917\u201331. https:\/\/doi.org\/10.1084\/jem.20122308.","journal-title":"J Exp Med"},{"key":"2223_CR51","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1002\/EJI.201646765","volume":"47","author":"H Bergmann","year":"2017","unstructured":"Bergmann H, Roth S, Pechloff K, Kiss EA, Kuhn S, Heikenw\u00e4lder M, et al. Card9-dependent IL-1\u03b2 regulates IL-22 production from group 3 innate lymphoid cells and promotes colitis-associated cancer. Eur J Immunol. 2017;47:1342\u201353. https:\/\/doi.org\/10.1002\/EJI.201646765.","journal-title":"Eur J Immunol"},{"issue":"1","key":"2223_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/ncomms14601","volume":"8","author":"ML Robinette","year":"2017","unstructured":"Robinette ML, Bando JK, Song W, Ulland TK, Gilfillan S, Colonna M. IL-15 sustains IL-7R-independent ILC2 and ILC3 development. Nat Commun. 2017;8(1):1\u201313. https:\/\/doi.org\/10.1038\/ncomms14601.","journal-title":"Nat Commun"},{"key":"2223_CR53","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1158\/0008-5472.CAN-16-0598","volume":"77","author":"S Irshad","year":"2017","unstructured":"Irshad S, Flores-Borja F, Lawler K, et al. ROR\u03b3t + innate lymphoid cells promote lymph node metastasis of breast cancers. Cancer Res. 2017;77:1083\u201396. https:\/\/doi.org\/10.1158\/0008-5472.CAN-16-0598.","journal-title":"Cancer Res"},{"key":"2223_CR54","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/J.EBIOM.2019.02.050","volume":"41","author":"Y Liu","year":"2019","unstructured":"Liu Y, Song Y, Lin D, Lei L, Mei Y, Jin Z, et al. NCR-group 3 innate lymphoid cells orchestrate IL-23\/IL-17 axis to promote hepatocellular carcinoma development. EBioMedicine. 2019;41:333\u201344. https:\/\/doi.org\/10.1016\/J.EBIOM.2019.02.050.","journal-title":"EBioMedicine"},{"key":"2223_CR55","doi-asserted-by":"publisher","DOI":"10.4161\/2162402X.2014.984539","volume":"4","author":"S Punt","year":"2015","unstructured":"Punt S, Fleuren GJ, Kritikou E, Lubberts E, Trimbos JB, Jordanova ES, et al. Angels and demons: Th17 cells represent a beneficial response, while neutrophil IL-17 is associated with poor prognosis in squamous cervical cancer. Oncoimmunology. 2015;4:984539. https:\/\/doi.org\/10.4161\/2162402X.2014.984539.","journal-title":"Oncoimmunology"},{"key":"2223_CR56","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/S12094-019-02160-5","volume":"22","author":"X Xuan","year":"2020","unstructured":"Xuan X, Zhou J, Tian Z, Lin Y, Song J, Ruan Z, et al. ILC3 cells promote the proliferation and invasion of pancreatic cancer cells through IL-22\/AKT signaling. Clin Transl Oncol. 2020;22:563\u201375. https:\/\/doi.org\/10.1007\/S12094-019-02160-5.","journal-title":"Clin Transl Oncol"},{"key":"2223_CR57","doi-asserted-by":"publisher","first-page":"5015","DOI":"10.1016\/J.CELL.2021.07.029","volume":"184","author":"J Goc","year":"2021","unstructured":"Goc J, Lv M, Bessman NJ, Flamar AL, Sahota S, Suzuki H, et al. Dysregulation of ILC3s unleashes progression and immunotherapy resistance in colon cancer. Cell. 2021;184:5015-5030.e16. https:\/\/doi.org\/10.1016\/J.CELL.2021.07.029.","journal-title":"Cell"},{"key":"2223_CR58","doi-asserted-by":"publisher","first-page":"8280","DOI":"10.1038\/NCOMMS9280","volume":"23","author":"P Carrega","year":"2015","unstructured":"Carrega P, Loiacono F, Di Carlo E, et al. NCR(+)ILC3 concentrate in human lung cancer and associate with intratumoral lymphoid structures. Nat Commun. 2015;23:8280. https:\/\/doi.org\/10.1038\/NCOMMS9280.","journal-title":"Nat Commun"},{"key":"2223_CR59","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1038\/NI.1947","volume":"11","author":"M Eisenring","year":"2010","unstructured":"Eisenring M, vom Berg J, Kristiansen G, et al. IL-12 initiates tumor rejection via lymphoid tissue-inducer cells bearing the natural cytotoxicity receptor NKp46. Nat Immunol. 2010;11:1030\u20138. https:\/\/doi.org\/10.1038\/NI.1947.","journal-title":"Nat Immunol"},{"key":"2223_CR60","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1038\/ni.3800","volume":"18","author":"Y Gao","year":"2017","unstructured":"Gao Y, Souza-Fonseca-Guimaraes F, Bald T, et al. Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells. Nat Immunol. 2017;18:1004\u201315. https:\/\/doi.org\/10.1038\/ni.3800.","journal-title":"Nat Immunol"},{"key":"2223_CR61","doi-asserted-by":"publisher","first-page":"910","DOI":"10.3389\/fimmu.2019.00910","volume":"1","author":"FR Mariotti","year":"2019","unstructured":"Mariotti FR, Quatrini L, Munari E, et al. Innate lymphoid cells: expression of PD-1 and other checkpoints in normal and pathological conditions. Front Immunol. 2019;1:910. https:\/\/doi.org\/10.3389\/fimmu.2019.00910.","journal-title":"Front Immunol"},{"key":"2223_CR62","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1136\/gutjnl-2021-325288","volume":"71","author":"B Heinrich","year":"2022","unstructured":"Heinrich B, Michael Gertz E, Sch\u00e4ffer AA, Craig AJ, Ruf B, Subramanyam V, et al. The tumor microenvironment shapes innate lymphoid cells in patients with hepatocellular carcinoma. Gut. 2022;71:1161\u201375. https:\/\/doi.org\/10.1136\/gutjnl-2021-325288.","journal-title":"Gut"},{"key":"2223_CR63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2022.849958","volume":"13","author":"B Heinrich","year":"2022","unstructured":"Heinrich B, Ruf B, Subramanyam V, Myojin Y, Lai CW, Craig AJ, et al. Checkpoint inhibitors modulate plasticity of innate lymphoid cells in peripheral blood of patients with hepatocellular carcinoma. Front Immunol. 2022;13:1\u201314. https:\/\/doi.org\/10.3389\/fimmu.2022.849958.","journal-title":"Front Immunol"},{"key":"2223_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-819609-0.00003-1","author":"B Kaminska","year":"2020","unstructured":"Kaminska B, Ciechomska IA, Cyranowski S. Autophagy in brain tumor immune evasion and responses to immunotherapy. Autophagy Immune Response Impact Cancer Immunother. 2020. https:\/\/doi.org\/10.1016\/B978-0-12-819609-0.00003-1.","journal-title":"Autophagy Immune Response Impact Cancer Immunother"},{"key":"2223_CR65","doi-asserted-by":"publisher","first-page":"215","DOI":"10.5114\/WO.2018.82642","volume":"22","author":"C Reiter-Brennan","year":"2018","unstructured":"Reiter-Brennan C, Semmler L, Klein A. The effects of 2-hydroxyglutarate on the tumorigenesis of gliomas. Contemp Oncol. 2018;22:215. https:\/\/doi.org\/10.5114\/WO.2018.82642.","journal-title":"Contemp Oncol"},{"key":"2223_CR66","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/nature08617","volume":"462","author":"L Dang","year":"2009","unstructured":"Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009;462:739\u201344. https:\/\/doi.org\/10.1038\/nature08617.","journal-title":"Nature"},{"key":"2223_CR67","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/S00401-013-1194-6","volume":"127","author":"MR Gilbert","year":"2014","unstructured":"Gilbert MR, Liu Y, Neltner J, Pu H, Morris A, Sunkara M, et al. Autophagy and oxidative stress in gliomas with IDH1 mutations. Acta Neuropathol. 2014;127:221\u201333. https:\/\/doi.org\/10.1007\/S00401-013-1194-6.","journal-title":"Acta Neuropathol"},{"key":"2223_CR68","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1007\/S10072-013-1607-2","volume":"35","author":"J Shi","year":"2014","unstructured":"Shi J, Zuo H, Ni L, Xia L, Zhao L, Gong M, et al. An IDH1 mutation inhibits growth of glioma cells via GSH depletion and ROS generation. Neurol Sci. 2014;35:839\u201345. https:\/\/doi.org\/10.1007\/S10072-013-1607-2.","journal-title":"Neurol Sci"},{"key":"2223_CR69","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/J.MEHY.2011.01.011","volume":"76","author":"J Zhu","year":"2011","unstructured":"Zhu J, Zuo J, Xu Q, Wang X, Wang Z, Zhou D. Isocitrate dehydrogenase mutations may be a protective mechanism in glioma patients. Med Hypotheses. 2011;76:602\u20133. https:\/\/doi.org\/10.1016\/J.MEHY.2011.01.011.","journal-title":"Med Hypotheses"},{"key":"2223_CR70","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1084\/JEM.20092506","volume":"207","author":"S Gross","year":"2010","unstructured":"Gross S, Cairns RA, Minden MD, Driggers EM, Bittinger MA, Jang HG, et al. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J Exp Med. 2010;207:339\u201344. https:\/\/doi.org\/10.1084\/JEM.20092506.","journal-title":"J Exp Med"},{"key":"2223_CR71","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.immuni.2009.04.019","volume":"31","author":"Y Li","year":"2009","unstructured":"Li Y, Hofmann M, Wang Q, Teng L, Chlewicki LK, Pircher H, et al. Structure of natural killer cell receptor KLRG1 bound to E-cadherin reveals basis for MHC-independent missing self recognition. Immunity. 2009;31:35. https:\/\/doi.org\/10.1016\/j.immuni.2009.04.019.","journal-title":"Immunity"},{"key":"2223_CR72","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1136\/annrheumdis-2013-203881","volume":"73","author":"L Melis","year":"2014","unstructured":"Melis L, Van Praet L, Pircher H, Venken K, Elewaut D. Senescence marker killer cell lectin-like receptor G1 (KLRG1) contributes to TNF-\u03b1 production by interaction with its soluble E-cadherin ligand in chronically inflamed joints. Ann Rheum Dis. 2014;73:1223\u201331. https:\/\/doi.org\/10.1136\/annrheumdis-2013-203881.","journal-title":"Ann Rheum Dis"},{"key":"2223_CR73","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1073\/pnas.1712625115","volume":"115","author":"J Han","year":"2018","unstructured":"Han J, Jackson D, Holm J, Turner K, Ashcraft P, Wang X, et al. Elevated D-2-hydroxyglutarate during colitis drives progression to colorectal cancer. Proc Natl Acad Sci USA. 2018;115:1057\u201362. https:\/\/doi.org\/10.1073\/pnas.1712625115.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2223_CR74","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1101\/gad.294991.116","volume":"31","author":"NM Amankulor","year":"2017","unstructured":"Amankulor NM, Kim Y, Arora S, Kargl J, Szulzewsky F, Hanke M, et al. Mutant IDH1 regulates the tumor-associated immune system in gliomas. Genes Dev. 2017;31:774\u201386. https:\/\/doi.org\/10.1101\/gad.294991.116.","journal-title":"Genes Dev"},{"key":"2223_CR75","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1172\/JCI90644","volume":"127","author":"G Kohanbash","year":"2017","unstructured":"Kohanbash G, Carrera DA, Shrivastav S, Ahn BJ, Jahan N, Mazor T, et al. Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas. J Clin Invest. 2017;127:1425\u201337. https:\/\/doi.org\/10.1172\/JCI90644.","journal-title":"J Clin Invest"},{"key":"2223_CR76","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0095-6","author":"L Bunse","year":"2018","unstructured":"Bunse L, Pusch S, Bunse T, Sahm F, Sanghvi K, Friedrich M, et al. Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate. Nat med. 2018. https:\/\/doi.org\/10.1038\/s41591-018-0095-6.","journal-title":"Nat med"},{"key":"2223_CR77","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1445454","volume":"7","author":"M B\u00f6ttcher","year":"2018","unstructured":"B\u00f6ttcher M, Renner K, Berger R, Mentz K, Thomas S, Elizabeth Cardenas-Conejo Z, et al. D-2-hydroxyglutarate interferes with HIF-1\u03b1 stability skewing T-cell metabolism towards oxidative phosphorylation and impairing Th17 polarization D-2-hydroxyglutarate interferes with HIF-1a stability skewing T-cell metabolism towards oxidative phosphoryla. Oncoimmunology. 2018;7:e1445454. https:\/\/doi.org\/10.1080\/2162402X.2018.1445454.","journal-title":"Oncoimmunology"},{"key":"2223_CR78","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1038\/nature23475","volume":"548","author":"T Xu","year":"2017","unstructured":"Xu T, Stewart KM, Wang X, Liu K, Xie M, Kyu Ryu J, et al. Metabolic control of TH17\/iTreg balance by an epigenetic mechanism. Nature. 2017;548:228\u201333. https:\/\/doi.org\/10.1038\/nature23475.","journal-title":"Nature"},{"key":"2223_CR79","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.ccr.2010.01.020","volume":"17","author":"PS Ward","year":"2010","unstructured":"Ward PS, Patel J, Wise DR, Abdel-Wahab O, Bennett BD, Coller HA, et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting \u03b1-Ketoglutarate to 2-Hydroxyglutarate. Cancer Cell. 2010;17:225\u201334. https:\/\/doi.org\/10.1016\/j.ccr.2010.01.020.","journal-title":"Cancer Cell"},{"key":"2223_CR80","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1101\/gad.217406.113","volume":"27","author":"JA Losman","year":"2013","unstructured":"Losman JA, Kaelin WG. What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer. Genes Dev. 2013;27:836. https:\/\/doi.org\/10.1101\/gad.217406.113.","journal-title":"Genes Dev"}],"container-title":["Inflammation Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00011-026-02223-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00011-026-02223-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00011-026-02223-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T03:04:20Z","timestamp":1775012660000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00011-026-02223-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":80,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2223"],"URL":"https:\/\/doi.org\/10.1007\/s00011-026-02223-8","relation":{},"ISSN":["1420-908X"],"issn-type":[{"value":"1420-908X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,1]]},"assertion":[{"value":"17 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Clinical Research Ethics Committee of Erciyes University School of Medicine on: January 23, 2019 (Approval No: 96681246), September 11, 2019 (Approval No: 2019\/604), and December 1, 2021 (Approval No: 21\/244).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"80"}}